Head-to-head evidence
Apatinib vs Ramucirumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGFR2 · full Non-Small Cell Lung Cancer pipeline
Apatinib
Developed by Jiangsu Hengrui Pharmaceuticals
NCT02332512 · Phase 3 · status unknown
This is a randomized, placebo-controlled trial with full blinding of participants, care providers, and assessors, using overall survival, a hard clinical endpoint, as its primary measure. Results have not yet been posted, so whether apatinib extended survival compared with placebo is not yet known.
Next expected readout: February 2027 · NCT07031154 (registry estimate)
Ramucirumab
Marketed by Eli Lilly
NCT01168973 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 628 participants assigned to ramucirumab plus docetaxel and 625 to placebo plus docetaxel, using overall survival as a hard clinical primary endpoint. Although the reported median survival favored ramucirumab, the registry does not state whether the primary comparison was statistically significant, so the result is unclear.
Next expected readout: December 2026 · NCT03909334 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apatinib's landscape · Ramucirumab's landscape